Autoimmune hepatitis and primary sclerosing cholangitis after direct-acting antiviral treatment for hepatitis C virus: A case report
CONCLUSION: The potential risk of developing autoimmune liver diseases after DAA treatment should be considered.PMID:38495284 | PMC:PMC10941733 | DOI:10.4254/wjh.v16.i2.286 (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - March 18, 2024 Category: Gastroenterology Authors: Yoshiki Morihisa Hobyung Chung Shuichiro Towatari Daisuke Yamashita Tetsuro Inokuma Source Type: research
Advancements in autoimmune hepatitis management: Perspectives for future guidelines
World J Hepatol. 2024 Feb 27;16(2):135-139. doi: 10.4254/wjh.v16.i2.135.ABSTRACTThe first-line treatment for autoimmune hepatitis involves the use of prednisone or prednisolone either as monotherapy or in combination with azathioprine (AZA). Budesonide has shown promise in inducing a complete biochemical response (CBR) with fewer adverse effects and is considered an optional first-line treatment, particularly for patients without cirrhosis; however, it is worth noting that the design of that study favored budesonide. A recent real-life study revealed higher CBR rates with prednisone when equivalent initial doses were admin...
Source: World Journal of Hepatology - March 18, 2024 Category: Gastroenterology Authors: Marcos Mucenic Source Type: research
Autoimmune hepatitis and primary sclerosing cholangitis after direct-acting antiviral treatment for hepatitis C virus: A case report
CONCLUSION: The potential risk of developing autoimmune liver diseases after DAA treatment should be considered.PMID:38495284 | PMC:PMC10941733 | DOI:10.4254/wjh.v16.i2.286 (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - March 18, 2024 Category: Gastroenterology Authors: Yoshiki Morihisa Hobyung Chung Shuichiro Towatari Daisuke Yamashita Tetsuro Inokuma Source Type: research
Advancements in autoimmune hepatitis management: Perspectives for future guidelines
World J Hepatol. 2024 Feb 27;16(2):135-139. doi: 10.4254/wjh.v16.i2.135.ABSTRACTThe first-line treatment for autoimmune hepatitis involves the use of prednisone or prednisolone either as monotherapy or in combination with azathioprine (AZA). Budesonide has shown promise in inducing a complete biochemical response (CBR) with fewer adverse effects and is considered an optional first-line treatment, particularly for patients without cirrhosis; however, it is worth noting that the design of that study favored budesonide. A recent real-life study revealed higher CBR rates with prednisone when equivalent initial doses were admin...
Source: World Journal of Hepatology - March 18, 2024 Category: Gastroenterology Authors: Marcos Mucenic Source Type: research
The impact of glucocorticoid use on the outcomes of rheumatoid arthritis in a multicenter ultrasound cohort study
ConclusionRA patients treated with glucocorticoids had a higher disease activity at baseline and a poorer response to treatments with b/tsDMARDs than those without glucocorticoids. The states of patients requiring glucocorticoids might be associated with the poor response to the b/tsDMARDs. (Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - March 15, 2024 Category: Rheumatology Authors: Fumiaki Nonaka,
Shoichi Fukui,
Tohru Michitsuji,
Yushiro Endo,
Ayako Nishino,
Toshimasa Shimizu,
Masataka Umeda,
Remi Sumiyoshi,
Tomohiro Koga,
Naoki Iwamoto,
Tomoki Origuchi,
Yukitaka Ueki,
Nobutaka Eiraku,
Takahisa Suzuki,
Akitomo Okada,
Tags: ORIGINAL ARTICLE Source Type: research
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
CONCLUSIONS: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.PMID:38485822 | DOI:10.1007/s44313-024-00006-w (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Naree Warnnissorn Nonglak Kanitsap Pimjai Niparuck Paisarn Boonsakan Prapasri Kulalert Wasithep Limvorapitak Lantarima Bhoopat Supawee Saengboon Chinnawut Suriyonplengsaeng Pichika Chantrathammachart Teeraya Puavilai Suporn Chuncharunee Source Type: research
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
CONCLUSIONS: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.PMID:38485822 | DOI:10.1007/s44313-024-00006-w (Source: Cell Research)
Source: Cell Research - March 15, 2024 Category: Cytology Authors: Naree Warnnissorn Nonglak Kanitsap Pimjai Niparuck Paisarn Boonsakan Prapasri Kulalert Wasithep Limvorapitak Lantarima Bhoopat Supawee Saengboon Chinnawut Suriyonplengsaeng Pichika Chantrathammachart Teeraya Puavilai Suporn Chuncharunee Source Type: research
Hand Foot Syndrome Induced by Lenvatinib - A Case Report
CONCLUSION: Hand-foot syndrome is one of the commonest ADRs due to the use of lenvatinib. Lenvatinib is an oral formulation that patients can take at their homes. Hence, educating patients regarding the HFS is important so that they report it to the treating physicians on time. It is also essential to educate patients regarding the precautions to be taken to avoid hand-foot syndrome. This will help the physicians with the early discontinuation and appropriate treatment with corticosteroids, which will help in improving the quality of life of the patients already suffering from cancer.PMID:38486391 | DOI:10.2174/01157488632...
Source: Current Drug Safety - March 15, 2024 Category: Drugs & Pharmacology Authors: Kiran Rangshahi Siddhartha Nanda Meenalotchini Prakash Gurunthalingam Vikas Katiyara Pugazhenthan Thangaraju Nitin R Gaikwad Source Type: research
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
CONCLUSIONS: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.PMID:38485822 | PMC:PMC10903517 | DOI:10.1007/s44313-024-00006-w (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Naree Warnnissorn Nonglak Kanitsap Pimjai Niparuck Paisarn Boonsakan Prapasri Kulalert Wasithep Limvorapitak Lantarima Bhoopat Supawee Saengboon Chinnawut Suriyonplengsaeng Pichika Chantrathammachart Teeraya Puavilai Suporn Chuncharunee Source Type: research
Hand Foot Syndrome Induced by Lenvatinib - A Case Report
CONCLUSION: Hand-foot syndrome is one of the commonest ADRs due to the use of lenvatinib. Lenvatinib is an oral formulation that patients can take at their homes. Hence, educating patients regarding the HFS is important so that they report it to the treating physicians on time. It is also essential to educate patients regarding the precautions to be taken to avoid hand-foot syndrome. This will help the physicians with the early discontinuation and appropriate treatment with corticosteroids, which will help in improving the quality of life of the patients already suffering from cancer.PMID:38486391 | DOI:10.2174/01157488632...
Source: Current Drug Safety - March 15, 2024 Category: Drugs & Pharmacology Authors: Kiran Rangshahi Siddhartha Nanda Meenalotchini Prakash Gurunthalingam Vikas Katiyara Pugazhenthan Thangaraju Nitin R Gaikwad Source Type: research
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
CONCLUSIONS: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.PMID:38485822 | PMC:PMC10903517 | DOI:10.1007/s44313-024-00006-w (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Naree Warnnissorn Nonglak Kanitsap Pimjai Niparuck Paisarn Boonsakan Prapasri Kulalert Wasithep Limvorapitak Lantarima Bhoopat Supawee Saengboon Chinnawut Suriyonplengsaeng Pichika Chantrathammachart Teeraya Puavilai Suporn Chuncharunee Source Type: research
Hand Foot Syndrome Induced by Lenvatinib - A Case Report
CONCLUSION: Hand-foot syndrome is one of the commonest ADRs due to the use of lenvatinib. Lenvatinib is an oral formulation that patients can take at their homes. Hence, educating patients regarding the HFS is important so that they report it to the treating physicians on time. It is also essential to educate patients regarding the precautions to be taken to avoid hand-foot syndrome. This will help the physicians with the early discontinuation and appropriate treatment with corticosteroids, which will help in improving the quality of life of the patients already suffering from cancer.PMID:38486391 | DOI:10.2174/01157488632...
Source: Current Drug Safety - March 15, 2024 Category: Drugs & Pharmacology Authors: Kiran Rangshahi Siddhartha Nanda Meenalotchini Prakash Gurunthalingam Vikas Katiyara Pugazhenthan Thangaraju Nitin R Gaikwad Source Type: research
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
CONCLUSIONS: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.PMID:38485822 | PMC:PMC10903517 | DOI:10.1007/s44313-024-00006-w (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Naree Warnnissorn Nonglak Kanitsap Pimjai Niparuck Paisarn Boonsakan Prapasri Kulalert Wasithep Limvorapitak Lantarima Bhoopat Supawee Saengboon Chinnawut Suriyonplengsaeng Pichika Chantrathammachart Teeraya Puavilai Suporn Chuncharunee Source Type: research
Hand Foot Syndrome Induced by Lenvatinib - A Case Report
CONCLUSION: Hand-foot syndrome is one of the commonest ADRs due to the use of lenvatinib. Lenvatinib is an oral formulation that patients can take at their homes. Hence, educating patients regarding the HFS is important so that they report it to the treating physicians on time. It is also essential to educate patients regarding the precautions to be taken to avoid hand-foot syndrome. This will help the physicians with the early discontinuation and appropriate treatment with corticosteroids, which will help in improving the quality of life of the patients already suffering from cancer.PMID:38486391 | DOI:10.2174/01157488632...
Source: Current Drug Safety - March 15, 2024 Category: Drugs & Pharmacology Authors: Kiran Rangshahi Siddhartha Nanda Meenalotchini Prakash Gurunthalingam Vikas Katiyara Pugazhenthan Thangaraju Nitin R Gaikwad Source Type: research
Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level
CONCLUSIONS: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.PMID:38485822 | PMC:PMC10903517 | DOI:10.1007/s44313-024-00006-w (Source: Blood Research)
Source: Blood Research - March 15, 2024 Category: Hematology Authors: Naree Warnnissorn Nonglak Kanitsap Pimjai Niparuck Paisarn Boonsakan Prapasri Kulalert Wasithep Limvorapitak Lantarima Bhoopat Supawee Saengboon Chinnawut Suriyonplengsaeng Pichika Chantrathammachart Teeraya Puavilai Suporn Chuncharunee Source Type: research
